Construction of an immune-related signature with prognostic value for colon cancer.
Colon cancer
Immune related gene
Nomogram
Signature
Tumor immune microenvironment
Journal
PeerJ
ISSN: 2167-8359
Titre abrégé: PeerJ
Pays: United States
ID NLM: 101603425
Informations de publication
Date de publication:
2021
2021
Historique:
received:
14
04
2020
accepted:
30
12
2020
entrez:
17
5
2021
pubmed:
18
5
2021
medline:
18
5
2021
Statut:
epublish
Résumé
Colon cancer is the third most common malignant tumor in the world. Although immunotherapy has been used in cancer treatment, there is still no first-line immunotherapy method for colon cancer. Therefore, it is essential to search for potential immunotherapy targets and molecular biomarkers for early diagnosis and prognosis. In this study, we downloaded transcriptome data from The Cancer Genome Atlas (TCGA) and immune-related genes from the ImmPort database. Then we filtered genes with prognostic value and constructed an immune-related signature. Patients were classified into low- and high-risk groups, and we exerted a series of analysis between the signature and clinical phenotypes. Additionally, we used protein-protein interaction networks, gene set enrichment analysis (GSEA) and single-sample gene-set enrichment analysis (ssGSEA) to explore the underlying mechanism of this signature. Furthermore, the accuracy of this signature was verified, using two data sets from Gene Expression Omnibus (GEO). We selected 12 immune-related genes to construct the immune-related signature. Low-risk group had a higher level of immunity compared to high-risk group. The expression level of HLA genes and checkpoint-related genes were statistically different in low- and high-risk groups. This signature showed its prognostic value in TCGA cohort and 2 GEO data sets. The signature also had strong correlation with TNM classification, stage, survival state and lymphatic invasion. The mechanism of the signature may be related to several transcription factors and CD8+ T cell in the tumor microenvironment. In conclusion, this immune-related signature is of great prognosis value for colon cancer and its biofunction might be correlated with HLA genes, checkpoint-related genes and high-infiltrating T cells in tumor tissues.
Sections du résumé
BACKGROUND
BACKGROUND
Colon cancer is the third most common malignant tumor in the world. Although immunotherapy has been used in cancer treatment, there is still no first-line immunotherapy method for colon cancer. Therefore, it is essential to search for potential immunotherapy targets and molecular biomarkers for early diagnosis and prognosis.
METHODS
METHODS
In this study, we downloaded transcriptome data from The Cancer Genome Atlas (TCGA) and immune-related genes from the ImmPort database. Then we filtered genes with prognostic value and constructed an immune-related signature. Patients were classified into low- and high-risk groups, and we exerted a series of analysis between the signature and clinical phenotypes. Additionally, we used protein-protein interaction networks, gene set enrichment analysis (GSEA) and single-sample gene-set enrichment analysis (ssGSEA) to explore the underlying mechanism of this signature. Furthermore, the accuracy of this signature was verified, using two data sets from Gene Expression Omnibus (GEO).
RESULTS
RESULTS
We selected 12 immune-related genes to construct the immune-related signature. Low-risk group had a higher level of immunity compared to high-risk group. The expression level of HLA genes and checkpoint-related genes were statistically different in low- and high-risk groups. This signature showed its prognostic value in TCGA cohort and 2 GEO data sets. The signature also had strong correlation with TNM classification, stage, survival state and lymphatic invasion. The mechanism of the signature may be related to several transcription factors and CD8+ T cell in the tumor microenvironment.
CONCLUSION
CONCLUSIONS
In conclusion, this immune-related signature is of great prognosis value for colon cancer and its biofunction might be correlated with HLA genes, checkpoint-related genes and high-infiltrating T cells in tumor tissues.
Identifiants
pubmed: 33996273
doi: 10.7717/peerj.10812
pii: 10812
pmc: PMC8106397
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e10812Informations de copyright
©2021 Lv et al.
Déclaration de conflit d'intérêts
The authors declare there are no competing interests.
Références
Int J Mol Sci. 2012 Sep 25;13(10):12153-68
pubmed: 23202889
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Biomed Pharmacother. 2019 Feb;110:312-318
pubmed: 30522017
Clin Exp Metastasis. 2009;26(7):663-71
pubmed: 19430935
Cancer Res. 2011 Dec 1;71(23):7226-37
pubmed: 21900397
Cold Spring Harb Perspect Med. 2018 Sep 4;8(9):
pubmed: 29229670
Cancer Res. 2017 Aug 15;77(16):4434-4447
pubmed: 28655790
Nature. 2018 Feb 22;554(7693):538-543
pubmed: 29443964
Am J Physiol Gastrointest Liver Physiol. 2005 Jun;288(6):G1274-82
pubmed: 15890713
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
Adv Exp Med Biol. 2009;656:85-106
pubmed: 19928355
Cancer Res. 2018 Sep 15;78(18):5340-5348
pubmed: 30026324
Gastroenterology. 2010 Jun;138(6):2101-2114.e5
pubmed: 20420949
Cancer Lett. 2017 Aug 10;401:63-71
pubmed: 28476483
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Cancer Microenviron. 2008 Dec;1(1):69-83
pubmed: 19308686
Semin Cell Dev Biol. 2015 Mar;39:26-34
pubmed: 25655947
Immunity. 2010 Dec 14;33(6):890-904
pubmed: 21167754
Biometrics. 2000 Jun;56(2):337-44
pubmed: 10877287
Oncogenesis. 2017 Apr 3;6(4):e308
pubmed: 28368388
Immunology. 2018 Jun;154(2):196-203
pubmed: 29460282
Clin Cancer Res. 2008 Jan 1;14(1):178-87
pubmed: 18172269
Cancer Immunol Res. 2018 Nov;6(11):1426-1441
pubmed: 30228206
Genes Dev. 2007 Oct 15;21(20):2525-38
pubmed: 17938238
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Nature. 2012 Jan 26;483(7387):100-3
pubmed: 22281684
Ann Oncol. 2013 Oct;24 Suppl 6:vi64-72
pubmed: 24078664
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Gastroenterology. 2011 May;140(6):1807-16
pubmed: 21530747
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Nature. 2009 Nov 5;462(7269):108-12
pubmed: 19847166
Cancer Res. 2013 Jun 15;73(12):3591-603
pubmed: 23633484
Gastroenterology. 2010 Jun;138(6):2073-2087.e3
pubmed: 20420947
JCI Insight. 2018 Nov 15;3(22):
pubmed: 30429368
Nat Commun. 2013;4:2612
pubmed: 24113773
Nat Immunol. 2013 Oct;14(10):1014-22
pubmed: 24048123
Mol Pharmacol. 2000 Sep;58(3):601-7
pubmed: 10953054